Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “eli lilly” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 169
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 169 pipeline programs matching "eli lilly" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

169 results for “eli lilly” Back to intelligence hub

Search results

Page 1 of 8
  1. 0.9% sodium chloride, Lepodisiran

    Eli Lilly Co.

    Atherosclerotic Cardiovascular Disease Elevated lp(a)

    phase 3 small molecule active

    1 trial
  2. 14V-MC-JAJK

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial
  3. 5 mg Tadalafil

    Eli Lilly and Company

    Benign Prostate Hyperplasia

    phase 3 small molecule completed

    1 trial
  4. ABEMACICLIB , FULVESTRANT

    Eli Lilly Co.

    Breast cancer

    phase 3 small molecule active

    1 trial
  5. Abemaciclib

    Eli Lilly and Company

    Breast Cancer

    phase 3 small molecule active

    1 trial
  6. Abemaciclib

    Eli Lilly and Company

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  7. Baricitinib

    Eli Lilly Co.

    Covid19 Corona Virus Infection

    phase 3 small molecule active

    1 trial
  8. Baricitinib

    Eli Lilly and Company

    Systemic Lupus Erythematosus

    phase 3 small molecule terminated

    1 trial
  9. Baricitinib

    Eli Lilly and Company

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial
  10. Clopidogrel

    Eli Lilly and Company

    Acute Coronary Syndrome

    phase 3 small molecule completed

    1 trial
  11. Drotrecogin alfa (activated)

    Eli Lilly and Company

    Sepsis

    phase 3 small molecule completed

    1 trial
  12. Duloxetine hydrochloride

    Eli Lilly and Company

    Diabetic Neuropathies

    phase 3 small molecule completed

    1 trial
  13. Eloralintide

    Eli Lilly and Company

    Obesity

    phase 3 small molecule active

    1 trial
  14. Galcanezumab, Placebo to match LY2951742

    Eli Lilly Co.

    Migraine

    phase 3 small molecule active

    1 trial
  15. Galcanezumab, Placebo to match LY2951742

    Eli Lilly Co.

    Chronic Migraine

    phase 3 small molecule active

    1 trial
  16. Glargine

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial
  17. H8H-MC-LAHV

    Eli Lilly Co.

    Migraine

    phase 3 small molecule active

    1 trial
  18. Human Insulin Inhalation Powder

    Eli Lilly and Company

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  19. I3Y-MC-JPCF

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial
  20. I3Y-MC-JPCM

    Eli Lilly Co.

    Prostate Cancer

    phase 3 small molecule active

    1 trial
  21. I3Y-MC-JPEF

    Eli Lilly Co.

    Breast Neoplasm, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial
  22. I4V-MC-JAHU

    Eli Lilly Co.

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial
  23. I4V-MC-JAHW

    Eli Lilly Co.

    Uveitis

    phase 3 small molecule active

    1 trial
  24. I4V-MC-JAHX

    Eli Lilly Co.

    Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.